# Candel Therapeutics share price today (Candel Therapeutics, Inc., CADL)

> Candel Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CADL · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/cadl

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $9.05 (+79.6% in a year)
- Revenue (Dec 2022): $31.0 K
- Profit (Dec 2022), incl. one-off: −$5.1 M (one-off item, see below)
- ROE: −39%, FY22

Biggest thing to watch: the price has already been rising for 2 weeks, so timing is the risk more than the business. ## What is the Candel Therapeutics share price today? Candel Therapeutics, Inc.'s share price was $9.05 at the close on 4 November 2026. It has been rising for 2 weeks. That is 8.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $5 and $13, and at that close it sat 52% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 4 weeks running. Over the last 5.3 years the share price moved +19% while the S&P 500 moved +67%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Candel Therapeutics pay? Candel Therapeutics, Inc. pays no dividend. In the last 7 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Candel Therapeutics on? Candel Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Candel Therapeutics profitable? Candel Therapeutics, Inc. posted a net loss of $5.1 M in the Dec 2022 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY22 year was a loss of $18.8 M. That loss is 16,396.8% of the quarter's revenue. The same quarter a year earlier earned $1.6 M. Dec 2022 profit was −$5.1 M, −418.5% on a year earlier. Read this profit with care: at −$5.1 M it is bigger than the quarter's whole revenue of $31.0 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −26,132.3% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Candel Therapeutics make, and is it growing? Candel Therapeutics, Inc. reported $31.0 K of revenue in the Dec 2022 quarter, +0.0% on the same quarter a year earlier. Over 1 years it has grown 0.0% a year on average. The last full year, FY22, came in at $125 K. The last four reported quarters add to $124 K. Recent pace: the last four quarters grew +0.0% on average, against 0.0% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. ## How much of every $100 of sales does Candel Therapeutics keep? Candel Therapeutics, Inc. has almost no sales yet: FY22 revenue was $125 K. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Candel Therapeutics' profit turning into cash? Candel Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY22 its operations used $31.4 M of cash, against −$18.8 M of profit. After $1.3 M of spending on assets, free cash was −$32.7 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Candel Therapeutics' cash go? Candel Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.1 M on assets over the last 2 years. Averaged over those years that is 1,252.8% of FY22 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.1 M over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Candel Therapeutics' P/E ratio, and how does it compare with its own history? Candel Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Candel Therapeutics, Inc. at 5,539.9× its FY22 revenue of $125 K. The P/E comes back here once profit turns positive. ## Is the Candel Therapeutics business getting better or worse? Candel Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Candel Therapeutics earn on its capital? Candel Therapeutics, Inc. earned a ROE of −39% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −33%, a number that says nothing useful about the business. ## Does Candel Therapeutics have too much debt? Candel Therapeutics, Inc. has total debt of $49.5 M against shareholder equity of $126 M as of Jun 2026, so its debt is 0.39× its equity. Year by year, that ratio went from 0.01 in FY21 to 0.94 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Candel Therapeutics shareholding pattern? 21.2% of Candel Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 12.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Candel Therapeutics from balance-sheet trouble? For Candel Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Candel Therapeutics rank in its industry? There is no score against its industry: Candel Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Candel Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Candel Therapeutics in size? Candel Therapeutics is the 127th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: XOMA Royalty Corporation, Solid Biosciences Inc. and Geron Corporation. Just below it: 4D Molecular Therapeutics, Inc., Kura Oncology, Inc. and Zevra Therapeutics, Inc. ### Biotechnology companies close in size

1. [XOMA Royalty Corporation](https://www.sectoralpha.in/us/stocks/xoma) $710 million
2. [Solid Biosciences Inc.](https://www.sectoralpha.in/us/stocks/sldb) $699 million
3. [Geron Corporation](https://www.sectoralpha.in/us/stocks/gern) $694 million
4. Candel Therapeutics, Inc. $692 million
5. [4D Molecular Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fdmt) $678 million
6. [Kura Oncology, Inc.](https://www.sectoralpha.in/us/stocks/kura) $677 million
7. [Zevra Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/zvra) $665 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [VTEX](https://www.sectoralpha.in/us/stocks/vtex) $693 million · Software - Application
2. [PennantPark Floating Rate Capital Ltd.](https://www.sectoralpha.in/us/stocks/pflt) $693 million · Asset Management
3. Candel Therapeutics, Inc. $692 million
4. [BlackSky Technology Inc.](https://www.sectoralpha.in/us/stocks/bksy) $686 million · Specialty Business Services
5. [ACNB Corporation](https://www.sectoralpha.in/us/stocks/acnb) $686 million · Banks - Regional

## What else do people ask about Candel Therapeutics? ### What were Candel Therapeutics's latest quarterly results? Candel Therapeutics, Inc. reported revenue of $31.0 K and a net loss of $5.1 M for the Dec 2022 quarter. Revenue rose 0.0% and profit fell 418.5% compared with a year earlier. Earnings per share were −$0.18. The operating margin was −26,132.3%, 1,164.6 percentage points lower than a year earlier (as of 4 November 2026). ### What is Candel Therapeutics's market cap? Candel Therapeutics, Inc.'s market capitalisation is $692 M at a stock price of $9.05. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### Is Candel Therapeutics growing? The picture is mixed for Candel Therapeutics, Inc. In the latest quarter, revenue was +0.0% on a year earlier and profit −418.5%, and the margin moved −1,164.6 percentage points to −26,132.3%. Over the last four quarters, results have been mixed (as of 4 November 2026). ### How is Candel Therapeutics performing? Candel Therapeutics, Inc.'s share price has been rising for 2 weeks. In its latest quarter, revenue rose 0.0% and profit fell 418.5% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 4 weeks running (as of 4 November 2026). ### Will Candel Therapeutics's stock price go up? This page does not forecast Candel Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $9.05, and it has been rising for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Candel Therapeutics story? Biggest thing to watch: the price has already been rising for 2 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Candel Therapeutics a stock worth studying right now? What the numbers show: Candel Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.